Skip to main content
Clinical Trials/CTRI/2018/08/015290
CTRI/2018/08/015290
Completed
未知

An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (CONCORDANCE) - CONCORDANCE

AstraZeneca Pharma India Ltd0 sites245 target enrollmentStarted: TBDLast updated:

Overview

Phase
未知
Status
Completed
Enrollment
245

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who provide written informed consent
  • 2\. Patients aged 18 years and older
  • 3\. Newly diagnosed patients with Metastatic (stage IV) NSCLC.
  • 4\. Histologically confirmed Adenocarcinoma NSCLC patients as per tissue biopsy and the sample sent for EGFR mutation analysis.
  • 5\. Patient should be naïve for any systemic treatment (i.e. no chemotherapy or EGFR\-TKI)
  • 6\. Provision of a routine blood (plasma) sample
  • The prescription of any medicinal product is clearly separated from the decision to include the subject in the study.

Exclusion Criteria

  • 1\. Patient with any medical condition that, in the opinion of the investigator, would interfere with outcome of the study
  • 2\. Patient participating in any other interventional clinical study/trial.

Investigators

Similar Trials